NYSE:BSX - Boston Scientific Stock Price, Price Target & More

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

Boston Scientific Co. (NYSE:BSX) released its quarterly earnings results on Wednesday, April, 25th. The medical equipment provider reported $0.33 EPS for the quarter, topping analysts' consensus estimates of $0.32 by $0.01. The medical equipment provider had revenue of $2.38 billion for the quarter, compared to analysts' expectations of $2.34 billion. Boston Scientific had a return on equity of 25.10% and a net margin of 1.21%. The firm's revenue was up 10.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.29 earnings per share. View Boston Scientific's Earnings History.

Boston Scientific is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Boston Scientific.

Boston Scientific updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided EPS guidance of $1.37-1.41 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.37. The company issued revenue guidance of $9.75-9.90 billion (+5-7% organic), compared to the consensus revenue estimate of $9.75 billion.Boston Scientific also updated its Q2 guidance to $0.33-0.35 EPS.

22 Wall Street analysts have issued 12-month target prices for Boston Scientific's shares. Their predictions range from $27.00 to $38.00. On average, they expect Boston Scientific's stock price to reach $32.8182 in the next year. This suggests that the stock has a possible downside of 2.3%. View Analyst Ratings for Boston Scientific.

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 3 hold ratings, 16 buy ratings and 3 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Boston Scientific saw a decline in short interest in June. As of June 15th, there was short interest totalling 11,140,076 shares, a decline of 22.5% from the May 31st total of 14,367,253 shares. Based on an average trading volume of 13,883,441 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.8% of the company's stock are short sold. View Boston Scientific's Current Options Chain.

Some companies that are related to Boston Scientific include 3M (MMM), Becton Dickinson and (BDX), Stryker (SYK), FRESENIUS SE &/S (FSNUY), Baxter International (BAX), ABIOMED (ABMD), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), ICU Medical (ICUI), Hill-Rom (HRC), Globus Medical (GMED), Insulet (PODD), Haemonetics (HAE) and Penumbra (PEN).

Media stories about BSX stock have been trending somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Boston Scientific earned a daily sentiment score of 0.10 on Accern's scale. They also gave news stories about the medical equipment provider an impact score of 46.62 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Boston Scientific's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Atalanta Sosnoff Capital LLC (0.09%), Gateway Investment Advisers LLC (0.06%), Bank of Montreal Can (0.06%), Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%), Xact Kapitalforvaltning AB (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Supratim Bose, Timothy A Pratt, Valley Gold Master Fund L Sun and Wendy Carruthers. View Institutional Ownership Trends for Boston Scientific.

BSX stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Gateway Investment Advisers LLC, Xact Kapitalforvaltning AB, Private Trust Co. NA and Banced Corp. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael P Phalen, Supratim Bose, Timothy A Pratt and Wendy Carruthers. View Insider Buying and Selling for Boston Scientific.

BSX stock was purchased by a variety of institutional investors in the last quarter, including Atalanta Sosnoff Capital LLC, State of Alaska Department of Revenue, IFM Investors Pty Ltd, Fjarde AP Fonden Fourth Swedish National Pension Fund, DnB Asset Management AS, Atria Investments LLC, Catawba Capital Management VA and Livforsakringsbolaget Skandia Omsesidigt. Company insiders that have bought Boston Scientific stock in the last two years include John E Sununu and Valley Gold Master Fund L Sun. View Insider Buying and Selling for Boston Scientific.

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BSX stock can currently be purchased for approximately $33.59.

Boston Scientific has a market capitalization of $46.02 billion and generates $9.05 billion in revenue each year. The medical equipment provider earns $105 million in net income (profit) each year or $1.26 on an earnings per share basis. Boston Scientific employs 29,000 workers across the globe.

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]